Segall Bryant & Hamill, LLC Immuno Gen, Inc. Transaction History

Segall Bryant & Hamill, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$3.75 - $20.05 $7.32 Million - $39.1 Million	-1,951,889 Reduced 86.99%	291,857 $5.51 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $113,102 - $151,624	-30,818 Reduced 1.35%	2,243,746 $8.62 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $10.3 Million - $14.4 Million	2,274,564 New	2,274,564 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $3.94 Million - $5.69 Million	878,961 New	878,961 $4.2 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $33,021 - $60,382	10,483 Added 1.24%	854,646 $3.85 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $3.6 Million - $6.31 Million	844,163 New	844,163 $4.02 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.